The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)

Publications

Ji FP, Li ZX, Deng H, Xue HA, Liu Y, Li M

Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C.

World journal of gastroenterology. 2010;16(35):4394-9

Slavenburg S, Heijdra YF, Drenth JP

Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.

Digestive diseases and sciences. 2010;55(3):579-85

Vartany E, Caldwell CA, Trow TK

Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.

Heart & lung : the journal of critical care. 2008;37(2):153-6

Fuhrmann V, Kramer L, Bauer E, Laferl H, Tucek G, Dekan G, Schenk P

Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection.

Digestive diseases and sciences. 2004;49(11-12):1966-70

Wolf Y, Haddad R, Jossipov J, Werbin N

Alpha-interferon induced severe pneumonitis.

Journal of toxicology. Clinical toxicology. 1997;35(1):113-4

Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K

Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C.

Chest. 1994;105(3):939-41